{"DataElement":{"publicId":"11334662","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia Present Type","preferredDefinition":"A response used to indicate Acute myeloid leukemia characterized present and to verify the type of cytogenetic abnormalities result in disruption of the transcription factor CBF.","longName":"11332301v1.00:11332303v1.00","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"11332301","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia Present","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.:Being or existing in a specified place or at the specified time.","longName":"5890017v1.00:2233878v1.00","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"5890017","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","longName":"C122688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52F7C36E-5687-3128-E053-F662850A774E","latestVersionIndicator":"Yes","beginDate":"2017-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-27","modifiedBy":"ONEDATA","dateModified":"2017-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233878","version":"1","preferredName":"Present","preferredDefinition":"Being or existing in a specified place or at the specified time.","longName":"C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F970CDF6-F829-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D188BD-58A6-712B-E053-731AD00A267C","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeDescription":"11/8/18 TT released/PClark. 6/27/17 tt, 10075.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"11332303","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia Type","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis._Something distinguishable as an identifiable class based on common qualities.","longName":"11332303v1.00","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"0","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CBF AML","valueDescription":null,"ValueMeaning":{"publicId":"11332304","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia","longName":"11332304v1.00","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1F9DE-1618-7CB6-E053-731AD00AB956","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D1F9DE-161A-7CB6-E053-731AD00AB956","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Non-CBF AML","valueDescription":null,"ValueMeaning":{"publicId":"11332305","version":"1","preferredName":"Negation Core Binding Factor Acute Myeloid Leukemia","longName":"11332305v1.00","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1F9DE-1619-7CB6-E053-731AD00AB956","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D1F9DE-161B-7CB6-E053-731AD00AB956","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Non-CBF, good/intermediate","valueDescription":null,"ValueMeaning":{"publicId":"11334659","version":"1","preferredName":"Good Intermediate Risk Negation Core Binding Factor Acute Myeloid Leukemia","longName":"11334659v1.00","preferredDefinition":"Valuable or useful or agreeable or pleasing._The potential future harm that may arise from some present action or attribute or condition is moderate._An operation in which a term denies or inverts the meaning of another term or construction._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Good","conceptCode":"C64975","definition":"Valuable or useful or agreeable or pleasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Intermediate Risk","conceptCode":"C102402","definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D28F3D-54E4-1814-E053-731AD00A23E5","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"KUMMEROA","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D28F3D-54E7-1814-E053-731AD00A23E5","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Non-CBF, high risk","valueDescription":null,"ValueMeaning":{"publicId":"11334660","version":"1","preferredName":"High Risk Acute Leukemia Negation Core Binding Factor Acute Myeloid Leukemia","longName":"11334660v1.00","preferredDefinition":"Acute leukemia patients are stratified into the high risk group when their minimal residual disease levels are higher than 0.05%._An operation in which a term denies or inverts the meaning of another term or construction._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Risk Acute Leukemia","conceptCode":"C122458","definition":"Acute leukemia patients are stratified into the high risk group when their minimal residual disease levels are higher than 0.05%.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D28F3D-54E5-1814-E053-731AD00A23E5","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D28F3D-54E8-1814-E053-731AD00A23E5","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Not applicable, CBF","valueDescription":null,"ValueMeaning":{"publicId":"11334661","version":"1","preferredName":"Not Applicable Core Binding Factor Acute Myeloid Leukemia","longName":"11334661v1.00","preferredDefinition":"Determination of a value is not relevant in the current context._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D28F3D-54E6-1814-E053-731AD00A23E5","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D28F3D-54E9-1814-E053-731AD00A23E5","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"11332302","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia Type","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis._Something distinguishable as an identifiable class based on common qualities.","longName":"11332302v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1ECA7-216B-7B2D-E053-731AD00A3C0E","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1ECA7-216C-7B2D-E053-731AD00A3C0E","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Core Binding Factor (CBF) AML","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D2A3D7-986B-1A2B-E053-731AD00A3D5E","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}